The newest reporting from every desk, ordered by publication time. New stories appear here immediately after publication.
The full randomized trial report strengthens the evidence behind a negative result first announced in 2025. It illustrates the gap between modifying a cellular stress pathway and preserving patients’ function.
A longitudinal analysis connects lower bone density with cognitive decline and regional brain changes. The findings suggest shared aging vulnerabilities, but do not establish that treating bone loss protects cognition.
The exploratory findings support further study of longer injection intervals after initial weight loss. Durability, long-term safety and clinical benefits remain unresolved.
A newly published international consensus outlines standards for personalized treatment of difficult bacterial infections. Its practical recommendations do not establish broad clinical efficacy or confer regulatory approval.
A new imaging study connects cellular chemistry with gene activity in aging mouse lung and skin. The approach could improve research on senescence, but human diagnostic use remains unvalidated.
The financing supports planned human testing of CID-165 in estrogen receptor-positive breast cancer. The investigational macrocycle remains preclinical, with no established patient benefit.
A prospective study connects microbiome development with later diabetes-related outcomes in genetically susceptible children. The findings support further biomarker research but do not establish a screening test or preventive treatment.
New research examines how mitochondrial stress affects the hippocampus. The findings add to animal evidence that biological sex influences vulnerability to brain aging.
The recommendation brings Zealand Pharma’s GLP-2 peptide therapy closer to European authorization. A randomized trial found reduced dependence on intravenous support, while final approval remains pending.
The September 18 decision adds an oral treatment option after endocrine therapy stops controlling advanced disease. Trial results support longer progression-free survival, while an overall-survival benefit remains unestablished.
A new research toolkit compares AI systems across biological datasets and introduces compact models trained for aging research. Its benchmark results support further computational testing but establish no clinical or longevity benefit.
A retrospective preprint identified 1,039 patients with documented use of the unapproved peptide. The findings reveal a surveillance gap while leaving treatment effectiveness and safety unresolved.